secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K/A
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0000950170-24-100065
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences discloses CEO/CFO compensation: $260k/$212k salary, stock options at $2.71
--------------------------------------------------------------------------------

- CEO Thomas Schaefer base salary $260k/yr; 2024 target bonus 50% as CEO, 40% as CFO prorated.
- CFO Mark Kawakami base salary $212,063/yr; 2024 target bonus 30% as CFO, 20% as VP Finance prorated.
- Each granted options to buy 20,000 shares at $2.71, vesting over 4 years (25% one-year cliff, 36 monthly).
- Schaefer and Kawakami receive 6-month severance (non-CIC) or 12-month plus full equity vest (CIC).
- Agreements expire third anniversary of July 5, 2024; at-will employment confirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017024100065/0000950170-24-100065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017024100065/rkda-20240702.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-100065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer